tissues of human beings and animals without excessive toxicity irritation allergic response or other problem complications commensurate with a reasonable benefit risk ratio as used herein u201c pharmaceutically acceptable salts u201d refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof the present invention extends to in vivo delivery of a therapeutic agent although the compositions described herein may conceivably improve any therapeutic substance with poor aqueous solubility characteristics the described compositions preferably contain a peptide a salt form thereof preferably present in the composition in a therapeutically effective amount to modulate the production of growth hormone typically this involves affecting the activity of target receptors associated with the production thereof wherein the administration of active substances inhibits induces or enhances the activity of the receptor when it is contacted with the active substance preferably the active substances will be those that have improved properties as compared to growth hormone releasing proteins previously known or in the absence of a delivery system in this regard certain forms of peptides for example esters are expected to enhance numerous desirable qualities including without limitation bioavailability absorption metabolism pharmacokinetics excretions duration rate of clearance and the like certain forms of peptides for example salts are also expected to enhance numerous desirable qualities including without limitation solubility stability crystallinity physical form polymorphism as well as imparting other manufacturing benefits such as ease of handling and the.